Floatz logo

NEPENTHE

Cesarean Delivery

Emory UniversitySmall moleculePhase 4 / ApprovedActive
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Cesarean Delivery cohort.

Asset / SponsorPhaseRating
Misoprostol
University of Texas at Austin
Phase 4BBB
Cefazolin
Michael Stitely
Phase 4BBB
(±)-1-BUTYL-2',6'-PIPECOLOXYLIDIDE MONOHYDROCHLORIDE
Duke University
Phase 4BB

Same molecule, other indications

NEPENTHE is also rated in:

PainDormant
BBB
Indicative ·
77 / 100
View asset →
cancer of unknown primary siteDormant
BBB
Indicative ·
75 / 100
View asset →
chronic pain syndromeDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →